Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The first European Society of Cardiology (ESC) guidelines on the management of cardiomyopathies (CMPs), published 1 year ago, remain highly relevant. These guidelines provide a comprehensive framework to manage the complexity of CMPs, consolidating previous approaches. All CMPs are now addressed systematically in one document. The ESC recommends a 'CMP-oriented' approach, emphasizing thorough clinical assessments and phenotype-first categorization into hypertrophic, dilated, arrhythmogenic, restrictive, and non-dilated left ventricular CMP. Despite the utility of this method, certain classifications, such as arrhythmogenic right ventricular CMP and the novel non-dilated left ventricular CMP, raise controversies. Key advances in the guidelines include the use of genetic testing and cardiac magnetic resonance imaging to refine diagnoses and inform treatment, especially for high-risk genotypes. These guidelines advocate for personalized, multidisciplinary care. Overall, they represent a significant step forward but highlight the evolving nature of CMP management as scientific understanding progresses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11836687 | PMC |
| http://dx.doi.org/10.1093/eurheartjsupp/suae096 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.
J Am Coll Cardiol
September 2025
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), although data on clinical outcomes for AF patients with such variants remain sparse.
Objectives: We aimed to study the prognostic implication of rare cardiomyopathy-associated pathogenic variants (CMP-PLP) in AF patients from large, well-phenotyped clinical trials.
Methods: CMP-PLP carriers were identified using exome sequencing in 5 multinational trials from the Thrombolysis in Myocardial Infarction study group (ENGAGE AF, FOURIER, SAVOR, PEGASUS, and DECLARE), with replication in the EAST-AFNET-4 trial.
Regional 4D Cardiac Magnetic Resonance Strain Predicts Cardiomyopathy Progression in Duchenne Muscular Dystrophy.
J Cardiovasc Magn Reson
August 2025
Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN; Indiana University School of Medicine, Indianapolis, IN. Electronic address:
Background: Cardiomyopathy (CMP) is the leading cause of death in Duchenne muscular dystrophy (DMD). Characterization of disease trajectory can be challenging, especially in early stages of CMP where onset and progression may vary. Traditional metrics from cardiovascular magnetic resonance (CMR) imaging such as LVEF (left ventricular ejection fraction) and LGE (late gadolinium enhancement) are often insufficient for assessing the pace of disease progression.
View Article and Find Full Text PDFCardiomyopathy as indication for pediatric heart transplantation.
JHLT Open
November 2025
Department of Pediatrics (Cardiology), Stanford University, Palo Alto, California.
Pediatric cardiomyopathy (CMP), with an incidence of approximately 1 in 100,000 children, remains a critical clinical challenge. Often progressive, these myocardial disorders frequently culminate in end-stage heart failure, establishing CMP as the primary indication for pediatric heart transplantation. Key considerations for transplantation include specific CMP etiologies and subtypes alongside established listing criteria and strategies to navigate waitlist complexities.
View Article and Find Full Text PDFPremature ventricular contraction-induced ventricular dysfunction in children without structural heart disease: a systematic review and meta-analysis.
Europace
August 2025
Paediatric Cardiology and Cardiac Arrhythmias Complex Unit, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio, 4, Rome 00165, Italy.
Aims: Premature ventricular contractions (PVCs) in paediatric patients often present a benign course. However, a minority of patients may develop left ventricular (LV) dysfunction, and risk factors are still under debate. The aim of this systematic review and meta-analysis was to analyse the prevalence of PVC-induced cardiomyopathy (CMP) and understand the risk factors in paediatric patients with PVCs and structurally normal hearts.
View Article and Find Full Text PDFThe efficacy and safety of hydroxychloroquine in patients with chronic inflammatory cardiomyopathy: a multicenter randomized study (HYPIC trial).
BMC Med
August 2025
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave, Wuhan, 430030, China.
Background: Chronic inflammatory cardiomyopathy (infl-CMP) is a long-term sequela caused by the chronicity of acute myocarditis, especially fulminant myocarditis (FM). Hydroxychloroquine (HCQ) may benefit these patients by inhibiting the excessive inflammatory response.
Methods: In this multicenter, randomized trial, we evaluated the efficacy and safety of HCQ in patients with chronic infl-CMP after FM.